Literature DB >> 19893331

Can the severity of dependence scale be usefully applied to 'ecstasy'?

Raimondo Bruno1, Allison J Matthews, Libby Topp, Louisa Degenhardt, Rapson Gomez, Matthew Dunn.   

Abstract

BACKGROUND/AIMS: Although use of 'ecstasy' (drugs sold as containing 3,4-methylenedioxymethamphetamine) is prevalent, it is typically infrequent, and treatment presentations involving ecstasy as a principal problem drug are relatively rare. Human case reports and animal literature suggest dependence potential, although there may be some unique aspects to this syndrome for ecstasy in comparison to other substances. The Severity of Dependence Scale (SDS) was examined to determine whether this could usefully identify 'dependent' ecstasy consumers.
METHODS: We conducted a cross-sectional survey of 1,658 frequent (at least monthly) ecstasy consumers across Australia, assessing drug use, associated harms and risk behaviours. Dependence was evaluated with the SDS, using a cut-off of > or =4 to identify potential 'dependence'.
RESULTS: One fifth of the participants were screened as potentially dependent. These individuals used ecstasy more frequently, in greater amounts, engaged more extensively in risk behaviours and reported greater role interference than other participants. These findings were independent of methamphetamine use or dependence. The underlying structure of the ecstasy SDS was bifactorial.
CONCLUSIONS: The SDS has demonstrated construct validity as a screening tool to identify ecstasy users at elevated risk of experiencing adverse consequences, including features of dependence. The underlying structure of dependence symptoms differs for ecstasy compared to other drug classes, and some dependent consumers use the drug infrequently. The unique neurotoxic potential and entactogenic effects of ecstasy may require a distinct nosological classification for the experience of dependence associated with the drug. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19893331     DOI: 10.1159/000253550

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  11 in total

Review 1.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

2.  Effective active vaccination against methamphetamine in female rats.

Authors:  J D Nguyen; P T Bremer; C S Hwang; S A Vandewater; K C Collins; K M Creehan; K D Janda; M A Taffe
Journal:  Drug Alcohol Depend       Date:  2017-04-14       Impact factor: 4.492

3.  Severity of club drug dependence and perceived need for treatment among a sample of adult club drug users in Shanghai, China.

Authors:  Yingying Ding; Na He; Steven Shoptaw; Meiyang Gao; Roger Detels
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-05-29       Impact factor: 4.328

4.  Addiction potential of phentermine prescribed during long-term treatment of obesity.

Authors:  E J Hendricks; M Srisurapanont; S L Schmidt; M Haggard; S Souter; C L Mitchell; D G De Marco; M J Hendricks; Y Istratiy; F L Greenway
Journal:  Int J Obes (Lond)       Date:  2013-05-17       Impact factor: 5.095

5.  The drug purity discounting task: Ecstasy use likelihood is reduced by probabilistic impurity according to harmfulness of adulterants.

Authors:  Sean B Dolan; Matthew W Johnson
Journal:  Drug Alcohol Depend       Date:  2020-01-20       Impact factor: 4.492

Review 6.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

Review 7.  The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.

Authors:  Thomas Steinkellner; Michael Freissmuth; Harald H Sitte; Therese Montgomery
Journal:  Biol Chem       Date:  2011-01       Impact factor: 3.915

8.  Understanding pathways to stimulant use: a mixed-methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe (ATTUNE): study protocol.

Authors:  Moritz Rosenkranz; Amy O'Donnell; Uwe Verthein; Heike Zurhold; Michelle Addison; Nienke Liebregts; Magdalena Rowicka; Miroslav Barták; Benjamin Petruželka; Eileen Fs Kaner; Marcus-Sebastian Martens
Journal:  BMJ Open       Date:  2019-08-10       Impact factor: 2.692

9.  The Severity of Dependence Scale (SDS) for Codeine: Preliminary Investigation of the Psychometric Properties of the SDS in an Online Sample of Codeine Users From the UK.

Authors:  Paolo Deluca; Michelle Foley; Jacklyn Dunne; Andreas Kimergård
Journal:  Front Psychiatry       Date:  2021-04-01       Impact factor: 4.157

Review 10.  3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Authors:  Jerrold S Meyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.